Abstract
Objective
One reason for the difficulty in accurate preoperative pathological diagnosis of major salivary gland tumors with fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) is the tendency of pleomorphic adenomas to have a high, standardized uptake value (SUV). The expression of glucose transporter 1 (GLUT1) and the quantity of GLUT1 messenger RNA (mRNA) were analyzed in specimens of pleomorphic adenoma to identify whether GLUT1 is responsible for the increased glucose uptake in FDG-PET examinations of these tumors.
Methods
Eighty salivary gland tumors resected at Yokohama City University Hospital were retrospectively investigated. FDG-PET was performed prior to surgery. PET images were evaluated by two experienced radiologists. GLUT1 was immunohistochemically stained, and GLUT1 mRNA density was quantified using real-time polymerase chain reaction in 10 of 40 pleomorphic adenomas.
Results
The pleomorphic adenomas stained positively for GLUT1, and there was significant correlation between the GLUT1 index and the SUV in FDG-PET.
Conclusions
GLUT1 is expressed in salivary gland pleomorphic adenomas. Furthermore, the GLUT1 index shows significant correlation with the SUV of FDGPET. This result suggests that GLUT1 plays an important role in increasing FDG uptake in salivary gland pleomorphic adenomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Uchida Y, Minoshima S, Kawata T, Motoori K, Nakano K, Kazama T, et al. Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors. Clin Nucl Med 2005;30:170–176.
Keyes JW Jr, Harkness BA, Greven KM, Williams DW III, Watson NE Jr, McGuirt WF. Salivary gland tumors: pretherapy evaluation with PET. Radiology 1994;192:99–102.
McGuirt WF, Keyes JW Jr, Greven KM, Williams DW III, Watson NE Jr, Cappellari JO. Preoperative identification of benign versus malignant parotid masses: a comparative study including positron emission tomography. Laryngoscope 1995;105:579–584.
Eneroth CM. Salivary gland tumors in the parotid gland, submandibular gland, and the palate region. Cancer 1971;27:1415–1418.
Moadel RM, Weldon RH, Katz EB, Lu P, Mani J, Stahl M, et al. Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-d-glucose. Cancer Res 2005;65:698–702.
Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004;25:11–17.
Okamura T, Kawabe J, Koyama K, Ochi H, Yamada R, Sakamoto H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions. Acta Otolaryngol Suppl 1998;538:209–213.
Warburg O. On the origin of cancer cells. Science 1956;123:309–314.
Horiuchi M, Yasuda S, Shohtsu A, Ide M. Four cases of Warthin’s tumor of the parotid gland detected with FDG PET. Ann Nucl Med 1998;12:47–50.
Matsuda M, Sakamoto H, Okamura T, Nakai Y, Ohashi Y, Kawabe J, et al. Positron emission tomographic imaging of pleomorphic adenoma in the parotid gland. Acta Otolaryngol Suppl 1998;538:214–220.
Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDGPET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785–2808.
Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxiainduced increase in FDG uptake in MCF7 cells. J Nucl Med 2001;42:170–175.
Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003;89:3–9.
Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654–662.
Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379–387.
Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002;43:173–180.
Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004;45:22–29.
Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004;109:926–932.
Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter GLUT1 in human cancers. Cancer Res 1996;56:1164–1167.
Mori Y, Tsukinoki K, Yasuda M, Miyazawa M, Kaneko A, Watanabe Y. Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol 2007;43:563–569.
Ohtake S, Cheng J, Ida H, Suzuki M, Ohshiro K, Zhang W, et al. Precancerous foci in pleomorphic adenoma of the salivary gland: recognition of focal carcinoma and atypical tumor cells by P53 immunohistochemistry. J Oral Pathol Med 2002;31:590–597.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Horiuchi, C., Tsukuda, M., Taguchi, T. et al. Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas. Ann Nucl Med 22, 693–698 (2008). https://doi.org/10.1007/s12149-008-0162-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-008-0162-z